Biosynex Completes Acquisition of Chembio Diagnostics, Inc.
April 27, 2023 16:30 ET
|
Chembio Diagnostics, Inc.
Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA:...
Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023
April 19, 2023 08:00 ET
|
Chembio Diagnostics, Inc.
MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following...
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
April 13, 2023 07:00 ET
|
Chembio Diagnostics, Inc.
STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that...
Chembio Stockholders Reminded to Tender Shares Before 6:00 P.M., New York City Time, on April 12, 2023
April 10, 2023 08:00 ET
|
Chembio Diagnostics, Inc.
MEDFORD, N.Y., April 10, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following...
Chembio’s CEO Letter to Stockholders
April 03, 2023 16:15 ET
|
Chembio Diagnostics, Inc.
MEDFORD, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following...
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
March 29, 2023 07:00 ET
|
Chembio Diagnostics, Inc.
STRASBOURG, France, March 29, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that...
Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023
March 21, 2023 07:00 ET
|
Chembio Diagnostics, Inc.
MEDFORD, N.Y., March 21, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following...
Chembio Announces Letter to Stockholders Regarding Tender Offer
March 15, 2023 07:00 ET
|
Chembio Diagnostics, Inc.
MEDFORD, N.Y., March 15, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following...
Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.
March 15, 2023 07:00 ET
|
Chembio Diagnostics, Inc.
STRASBOURG, France, March 15, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that...
Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System
February 24, 2023 08:00 ET
|
Chembio Diagnostics, Inc.
MEDFORD, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a...